# LAG-3 Pioneer Immutep Fails Phase 3 Lung Cancer Study, Stock Crashes 88% - Date: 2026-03-14 - Category: Biotech & Life Sciences Australian biotech's lead drug eftilagimod alfa falls short in pivotal NSCLC trial, dealing another blow to the once-promising LAG-3 checkpoint target ---